OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

CPTAC Releases Lung Adenocarcinoma (LUAD) Proteomic Dataset

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to release its newest comprehensive dataset - deep proteomic/phosphoproteomic data and imaging data of Lung Adenocarcinoma (LUAD) patient tumors.  The CPTAC Tumor Characterization Program uses proteogenomic analysis to...


Congratulations to the Best Performers of the precisionFDA/NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Correction Big Data Challenge

Riding the wave of the future requires scientists to move away from silo-thinking to an inclusive and collaborative mind set. By leveraging the power of crowdsourcing, precisionFDA and NCI-CPTAC teamed up to launch the Multi-omics Enabled Sample Mislabeling Correction Big Data Challenge. Over...


CPTAC Researchers Analyze Colon Cancer Proteins and Genes to Uncover New Potential Treatments

Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.


Perspective on the clinical potential of mass spectrometry-based proteogenomics

Is DNA sequencing enough to recommend personalized treatments for cancer patients? In a article published in Nature Reviews Clinical Oncology, CPTAC investigators and colleagues from the Fred Hutch, Baylor College of Medicine, and University of Washington Medicine make the case for...


CPTAC Genomic Data Now Available in the NCI Genomic Data Commons (GDC)

CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer....


Be Part of Tomorrow’s Next-Gen Big Data Scientists (BD-STEP Training Fellowship Announcement)

"Big data" is a term to describe data sets so large or complex that traditional data processing strategies are inadequate. As continued advancements in biomedical technologies generate an increasing amount of patient data, administration of patient-centered care will depend, in part, on the...


precisionFDA/NCI-CPTAC Challenge Top Performers to Present at RECOMB2019 DREAM Satellite Conference

In February 2019, the precisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) proudly announced the best performers in the first-ever...


CPTAC Researchers Develop A Freely Available Database for Phosphosite-Specific Signature Analysis

It is no coincidence that one cellular process is mentioned time and time again in discussions of cell-signaling pathways in cancer - that is phosphorylation. Since its discovery, it has come to be recognized as a global regulator of many intracellular processes such as growth, proliferation,...


Best Performers Announced! - precisionFDA NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge

In biomedical research, sample mislabeling, or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...


Researchers Team Up to Catalog the Landscape of Circular RNA in Cancer

University of Michigan Rogel Cancer Center researchers Arul Chinnaiyan, Alexey Nesvizhskii and colleagues have recently teamed up to catalog circular RNA (circRNA) in multiple cancers and conducted initial research that suggests these stable structures could serve as cancer markers in blood or...


Pages